Altered Intestinal Microbiota Composition, Antibiotic Therapy and Intestinal Inflammation in Children and Adolescents with Cystic Fibrosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Jun 23

PMID 29933382

Citations 36

Authors

Maiara Brusco de Freitas

Emilia Addison Machado Moreira

Camila Tomio

Yara Maria Franco Moreno

Felipe Perozzo Daltoe

Eliana Barbosa

Norberto Ludwig Neto

Vittoria Buccigrossi

Alfredo Guarino

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to evaluate the effect of cystic fibrosis and antibiotic therapy on intestinal microbiota composition and intestinal inflammation in children and adolescents. A cross-sectional controlled study was conducted with 36 children and adolescents: 19 in the cystic fibrosis group (CFG) and 17 in the control group (CG) matched for age and sex. The CFG was subdivided based on the use of antibiotic therapy (CFAB group) and non-use of antibiotic therapy (CFnAB group). The following data were evaluated: colonization, antibiotic therapy, mutation, breastfeeding, use of infant formula, type of delivery, introduction of solid foods, body mass index, fecal calprotectin and intestinal microbiota composition (fluorescence in situ hybridization). Intestinal inflammation evaluated by fecal calprotectin was significantly higher in the CFG (median: 40.80 µg/g, IQR: 19.80-87.10, p = 0.040) and CFAB group (median: 62.95 µg/g, IQR: 21.80-136.62, p = 0.045) compared to the CG (median: 20.15 µg/g, IQR: 16.20-31.00), and the Bacteroides, Firmicutes, Eubacterium rectale and Faecalibacterium prausnitzii were significantly decreased (p < 0.05) in the CFG compared to the CG, whereas the bacteria Clostridium difficile, Escherichia coli and Pseudomonas aeruginosa were significantly increased in the CFG (p < 0.05). The main differences were found between the CG and CFAB group for Eubacterium rectale (p = 0.006), Bifidobacterium (p = 0.017), Escherichia coli (p = 0.030), Firmicutes (p = 0.002), Pseudomonas aeruginosa (p < 0.001) and Clostridium difficile (p = 0.006). The results of this study confirm intestinal inflammation in patients with CF, which may be related to changes in the composition of the intestinal microbiota.

Citing Articles

Effects of Therapeutic Antibiotic Exposure on the Oropharyngeal and Fecal Microbiota in Infants With Cystic Fibrosis.

Hayden H, Nelson M, Ross S, Verster A, Bouzek D, Eng A Pediatr Pulmonol. 2025; 60(3):e71024.

PMID: 40042126 PMC: 11881217. DOI: 10.1002/ppul.71024.

Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?.

Drzymala-Czyz S, Walkowiak J, Colombo C, Alicandro G, Storrosten O, Kolsgaard M iScience. 2024; 27(11):111153.

PMID: 39620135 PMC: 11607544. DOI: 10.1016/j.isci.2024.111153.

Impact of high-dose cholecalciferol (vitamin D3) and inulin prebiotic on intestinal and airway microbiota in adults with cystic fibrosis: A 2 × 2 randomized, placebo-controlled, double-blind pilot study.

Suppakitjanusant P, Wang Y, Sivapiromrat A, Hu C, Binongo J, Hunt W J Clin Transl Endocrinol. 2024; 37:100362.

PMID: 39188269 PMC: 11345930. DOI: 10.1016/j.jcte.2024.100362.

Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin D) (Pre-D trial) in adults with....

Sivapiromrat A, Suppakitjanusant P, Wang Y, Hu C, Binongo J, Hunt W Contemp Clin Trials Commun. 2024; 38:101278.

PMID: 38435430 PMC: 10904905. DOI: 10.1016/j.conctc.2024.101278.

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin D) (Pre-D Trial) in adults with....

Sivapiromrat A, Suppakitjanusant P, Wang Y, Binongo J, Hunt W, Gewirtz A medRxiv. 2024; .

PMID: 38343811 PMC: 10854319. DOI: 10.1101/2024.01.04.24300860.

References

Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee J . Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2014; 60(4):521-6. DOI: 10.1097/MPG.0000000000000683. View

Norkina O, Burnett T, De Lisle R . Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun. 2004; 72(10):6040-9. PMC: 517588. DOI: 10.1128/IAI.72.10.6040-6049.2004. View

Borowitz D, Baker R, Stallings V . Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002; 35(3):246-59. DOI: 10.1097/00005176-200209000-00004. View

Russell D, Ross R, Fitzgerald G, Stanton C . Metabolic activities and probiotic potential of bifidobacteria. Int J Food Microbiol. 2011; 149(1):88-105. DOI: 10.1016/j.ijfoodmicro.2011.06.003. View

Dethlefsen L, Huse S, Sogin M, Relman D . The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008; 6(11):e280. PMC: 2586385. DOI: 10.1371/journal.pbio.0060280. View

Hoffman L, Pope C, Hayden H, Heltshe S, Levy R, McNamara S . Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis. Clin Infect Dis. 2013; 58(3):396-9. PMC: 3890337. DOI: 10.1093/cid/cit715. View

Leffler D, Lamont J . Clostridium difficile infection. N Engl J Med. 2015; 372(16):1539-48. DOI: 10.1056/NEJMra1403772. View

Burke D, Harrison M, Fleming C, McCarthy M, Shortt C, Sulaiman I . Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J Cyst Fibros. 2016; 16(2):291-298. DOI: 10.1016/j.jcf.2016.09.008. View

Pereira L, Moreira E, Bennemann G, Moreno Y, da Silva Buss Z, Barbosa E . Influence of inflammatory response, infection, and pulmonary function in cystic fibrosis. Life Sci. 2014; 109(1):30-6. DOI: 10.1016/j.lfs.2014.06.002. View

10.

Bruzzese E, Callegari M, Raia V, Viscovo S, Scotto R, Ferrari S . Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One. 2014; 9(2):e87796. PMC: 3929570. DOI: 10.1371/journal.pone.0087796. View

11.

Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O . Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2010; 45(6):536-40. DOI: 10.1002/ppul.21138. View

12.

Schippa S, Iebba V, Santangelo F, Gagliardi A, De Biase R, Stamato A . Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients. PLoS One. 2013; 8(4):e61176. PMC: 3629184. DOI: 10.1371/journal.pone.0061176. View

13.

Hawrelak J, Myers S . The causes of intestinal dysbiosis: a review. Altern Med Rev. 2004; 9(2):180-97. View

14.

Yasmin F, Tun H, Konya T, Guttman D, Chari R, Field C . Cesarean Section, Formula Feeding, and Infant Antibiotic Exposure: Separate and Combined Impacts on Gut Microbial Changes in Later Infancy. Front Pediatr. 2017; 5:200. PMC: 5622971. DOI: 10.3389/fped.2017.00200. View

15.

Palmer C, Bik E, DiGiulio D, Relman D, Brown P . Development of the human infant intestinal microbiota. PLoS Biol. 2007; 5(7):e177. PMC: 1896187. DOI: 10.1371/journal.pbio.0050177. View

16.

Rautava S, Luoto R, Salminen S, Isolauri E . Microbial contact during pregnancy, intestinal colonization and human disease. Nat Rev Gastroenterol Hepatol. 2012; 9(10):565-76. DOI: 10.1038/nrgastro.2012.144. View

17.

Lynch S, Goldfarb K, Wild Y, Kong W, De Lisle R, Brodie E . Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes. 2012; 4(1):41-7. PMC: 3555885. DOI: 10.4161/gmic.22430. View

18.

De Lisle R, Borowitz D . The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013; 3(9):a009753. PMC: 3753720. DOI: 10.1101/cshperspect.a009753. View

19.

Daims H, Bruhl A, Amann R, Schleifer K, Wagner M . The domain-specific probe EUB338 is insufficient for the detection of all Bacteria: development and evaluation of a more comprehensive probe set. Syst Appl Microbiol. 1999; 22(3):434-44. DOI: 10.1016/S0723-2020(99)80053-8. View

20.

Yatsunenko T, Rey F, Manary M, Trehan I, Dominguez-Bello M, Contreras M . Human gut microbiome viewed across age and geography. Nature. 2012; 486(7402):222-7. PMC: 3376388. DOI: 10.1038/nature11053. View